What is ILMN's market cap?

$34.25B, based on the Nov 4 close of $226.54.

What is ILMN's P/E ratio?

38.3× trailing-twelve-month earnings of $895M.

Does Illumina pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ILMN is sold short?

7.9M shares, 5.5% of float, as of Oct 15, 2026.

What sector is ILMN in?

Healthcare, in the Lab Analytical Instruments industry.

NASDAQ · ILMNHealthcareLab Analytical Instruments

Illumina Inc (ILMN)

$226.54−4.90%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$238.21▲ 98.52% in range

Nov 3, 2025Low $114.44 · High $293.69Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Illumina closed at $226.54 on Nov 4, down 4.90%, 22.9% below its 52-week closing high. Volume of 3.0M shares was 1.31× its 20-day average (above normal).

Split-adjusted performance: -17.2% over one month, +58.9% over six months, +88.8% over one year.

In the quarter ended Sep 27, 2026, revenue was $1.13B, up 4.2% from a year earlier, with a net margin of 19.5%.

Short interest was 7.9M shares at the Oct 15 settlement, down 16.7% from the prior report (5.5% of float, 2.9 days to cover).

Market cap$34.25B151.2M shares

Revenue · quarter$1.13B+4.2% YoY

Diluted EPS$1.43+45.9% YoY

P/E · TTM38.3×P/S 7.5×

Net margin19.5%Gross 73.5%

Dividend yieldNone

52-week range114.44 – 293.69−22.9% from high

Volume3.0M1.31× 20-day avg

Volatility · 60d68.3%Annualised

Short % of float5.5%2.9 days to cover

Net cash-$452.0MCash $1.34B

Next earnings—Not scheduled

Split-adjusted performance

1W −21.6%1M −17.2%3M +16.9%6M +58.9%YTD +72.7%1Y +88.8%3Y +110.0%5Y −45.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum80

Revenue growth37

Net margin91

Value (low P/E)—

Size86

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →

Shares short7.9M−16.7% vs prior

Days to cover2.9Settled Oct 15

% of float5.5%

Short vol. 10d44.0%of daily volume

Closest peers by size in Lab Analytical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ILMNIllumina	$226.54	−4.90%	+58.9%	+4.2%	19.5%	38.3	$34.25B
MTDMettler-Toledo International	$1,723.24	+1.48%	+29.9%	+4.5%	22.7%	38.1	$34.53B	Compare
WATWaters	$467.60	+1.67%	+33.8%	+113.4%	−8.3%	276.5	$45.94B	Compare
AAgilent Technologies	$177.17	+0.97%	+50.5%	+8.1%	19.3%	34.7	$49.95B	Compare
RVTYRevvity	$159.43	−2.48%	+60.9%	+1.3%	7.1%	74.9	$17.79B	Compare
AVTRAvantor	$15.65	+0.38%	+85.6%	+4.6%	12.0%	31.4	$10.60B	Compare
BIOBio-Rad Laboratories	$379.99	+1.35%	+46.7%	−0.1%	57.1%	45.7	$10.16B	Compare
BIO.BBio-Rad Laboratories	$379.50	+4.22%	—	−0.1%	57.1%	45.6	$10.15B	Compare
BRKRBruker	$63.79	+12.90%	+50.8%	+5.2%	−7.5%	—	$9.72B	Compare

News about Illumina

All news →

Why Illumina (ILMN) is a Top Growth Stock for the Long-TermZacks Investment Research · 2d ago▲ Positive ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical GrowthZacks Investment Research · 5d ago▲ Positive Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research · 6d ago▲ Positive Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research · Oct 22, 2026▲ Positive Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 16, 2026▲ Positive

Quick answers

What does Illumina do?: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services.
What is ILMN's market cap?: $34.25B, based on the Nov 4 close of $226.54.
What is ILMN's P/E ratio?: 38.3× trailing-twelve-month earnings of $895M.
Does Illumina pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ILMN is sold short?: 7.9M shares, 5.5% of float, as of Oct 15, 2026.
What sector is ILMN in?: Healthcare, in the Lab Analytical Instruments industry.

About Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

HQ: San Diego, CA8,650 employeesListed Jul 28, 2000illumina.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology